Summary: Neonatal Fc receptor (FcRn) plays an important role in regulating IgG homeostasis in the body. Changes in FcRn expression levels or activity caused by genetic polymorphisms of FCGRT, which encodes FcRn, may lead to interindividual differences in pharmacokinetics of therapeutic antibodies. In this study, we sequenced the 5?-flanking region, all exons and their flanking regions of FCGRT from 126 Japanese subjects. Thirty-three genetic variations, including 17 novel ones, were found. Of these, two novel non-synonymous variations, 629GÀA (R210Q) and 889TÀA (S297T), were found as heterozygous variations. We next assessed the functional significance of the two novel non-synonymous variations by expressing wild-type and variant proteins in HeLa cells. Both variant proteins showed similar intracellular localization as well as antibody recycling efficiencies. These results suggested that at least no common functional polymorphic site with amino acid change was present in the FCGRT of our Japanese population.
Introduction
Neonatal Fc receptor (FcRn) is an immunoglobulin G (IgG) receptor related to major histocompatibility (MHC) class I molecules. 1, 2) Like MHC class I, FcRn consists of a heavy chain with extracellular a1, a2, and a3 domains followed by a transmembrane segment and a short cytoplasmic tail and non-covalently bound b2-microglobulin (b2m). FcRn binds the Fc region of monomeric IgG. The FcRn heavy chain is encoded by FCGRT, which is located in chromosome 19q13.3 and comprises 6 exons.
In humans, FcRn expression has been observed in a wide variety of tissues including placenta, liver, kidney and vascular endothelium. 1) FcRn has multiple roles in the body such as absorption or secretion of IgG across the intestinal mucosa, and IgG recycling from endothelial cells. With regard to antibody recycling, FcRn binds to the Fc domain of IgG at acidic pH in endosomes after endocytosis, and recycles it back to the extracellular space via the exocytic pathway, thereby protecting IgG from intracellular degradation in lysosomes. 2) This mechanism contributes to the long serum half-life of IgG, and thus, IgG recycling activity is an important function of FcRn and could contribute to the efficacy of antibody therapeutics. Indeed, we previously reported that affinities of antibody therapeutics to FcRn were closely correlated with the serum half-lives reported in clinical studies.
3)
The relatively short serum half-life of Fc-fusion proteins such as etanercept, a fusion protein consisting of the extracellular ligand-binding portion of the human tumor necrosis factor receptor linked to the Fc portion of human IgG1, is thought to arise from low affinity to FcRn. 3) Genetic polymorphisms of genes related to drug metabolism and transport are one of the crucial factors for low-molecular-weight drugs. Pharmacokinetics or pharmacodynamics of biologicals including antibody therapeutics may also be influenced by genetic polymorphisms of transport or target proteins. In this context, changes in FcRn expression levels or activity caused by genetic polymorphisms of FCGRT may lead to interindividual differences in pharmacokinetics of antibody therapeutics. However, reports on FCGRT genetic polymorphisms in Japanese populations are lacking.
Here we sequenced the 5?-flanking region, all exons and their flanking regions of FCGRT from 126 Japanese subjects. We then examined the functional properties of two detected non-synonymous variations using mammalian expression systems focusing on intracellular localization and antibody recycling activities.
Materials and Methods
Human genomic DNA samples: One hundred twenty-six Japanese cancer patients participated in this study. The ethical review boards of the National Cancer Center, Aichi Cancer Center and the National Institute of Health Sciences approved this study. Written informed consent was obtained from all subjects. Genomic DNA for DNA sequencing was extracted from blood leukocytes.
PCR conditions for DNA sequencing: The following sequences obtained from GenBank were used for primer design and reference sequences: NW_927240.1 (genome) and NM_004107.3 (mRNA). For sequencing, two sets of long-range PCR were performed to amplify all 6 exons from 50 ng of genomic DNA with two sets of primers (0.5 mM) designed in the promoter or intronic regions as listed in``1st PCR'' of Table 1 . We used LATaq with GC buffer I (0.05 U/ml, Takara Bio Inc., Shiga, Japan) to amplify from the 5?-flanking region to exon 3 and Z-Taq (0.025 U/ml, Takara Bio. Inc.) from exons 4 to 6, as described in Table 1 . The 1st PCR conditions were 949 C for 5 min, followed by 30 cycles of 949 C for 30 sec, 609 C for 1 min, and 729 C for 2 min, and then a final extension at 729 C for 7 min for LA-Taq, and 30 cycles of 989 C for 5 sec, 559 C for 5 sec, and 729 C for 190 sec for Z-Taq. Next, each region was separately amplified in the 2nd PCR using the 1st PCR product as the template. We used LA-Taq with GC buffer I or II (0.05 U/ml) for amplifying regions from the 5?-flanking region to exon 3 and Ex-Taq (0.02 U/ml, Takara Bio. Inc.) from exons 4 to 6 as described in Table 1 . The 2nd PCR conditions were 949 C for 5 min, followed by 30 cycles of 949 C for 30 sec, 609 C for 1 min, and 729 C for 2 min, and then a final extension at 729 C for 7 min for all regions. The PCR products were then treated with a PCR Product Pre-Sequencing Kit (USB Co., Cleveland, OH, USA) and directly sequenced on both strands using an ABI BigDye Terminator Cycle Sequencing Kit ver. 3.1 (Applied Biosystems, Foster City, CA, USA) and the sequencing primers listed in Table 1 (Sequencing). Excess dye was removed by a DyeEx96 kit (Qiagen, Hilden, Germany) and the eluates were applied to an ABI Prism 3730xl DNA Analyzer (Applied Biosystems). All relatively low frequent variations (nÃ5) were confirmed by repeated sequencing analyses of PCR products generated from original (not amplified) genomic DNA. The nucleotide positions based on the cDNA sequence were numbered from the adenine of the translational initiation site or the nearest exons.
Hardy-Weinberg equilibrium and linkage disequilibrium (LD) analyses: Hardy-Weinberg equilibrium and LD analyses were performed by SNPAlyze software ver. 7 (Dynacom Co., Yokohama, Japan). HardyWeinberg equilibrium was assessed by the x2 test and pairwise LDs between variations were obtained for the frequently used coefficients`D?`and rho square (r 2 ). D?`is used to assess the probability for past recombinations, and r 
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Construction of FcRn expression plasmid:
Wild-type human FcRn cDNA was originally obtained from pME18SFL3 (AK075532) (Toyobo, Osaka, Japan). The coding region of FcRn cDNA subcloned into pcDNA3 was amplified by PCR, and then inserted into the EcoRI/SalI site of pEGFP-(C) plasmid. The resulting plasmid encodes hFcRn with C-terminally fused enhanced green fluorescent protein (EGFP) containing the eight amino acid-linker peptide VDSRGSRV between the two proteins. Mutations were introduced by an inverse PCR method. Primers consisted of 5?-AAG GCC CAA CCC AGC AGC CCT GGC TTT-3? (forward) and 5?-CAG GCG CAT GGA GGG GGG CC CTT CCA-3? (reverse) for R210Q, 5?-TCC ACC GTC CTC GTG GTG GGA ATC GTC-3? (forward) and 5?-CTT GGC TGG AGA TTC CAG CTC CAC CCT-3? (reverse) for S297T. The underlines indicate the mutated nucleotides. The variant plasmids were sequenced on both strands for the entire cDNA region to confirm the introduction of the mutation only at the target sites. Human b2 microglobulin (b2m) cDNA was obtained from pME18SFL3 (FCC106E07) (Toyobo). b2m cDNA was subcloned into pcDNA3.1/ Hygro. The b2m construct was used because FcRn becomes a heterodimer with b2m, which is necessary for the proper intracellular localization of FcRn. 4, 5) Cell culture and plasmid transfection: HeLa cells were cultured in DMEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal calf serum (Nichirei, Tokyo, Japan). The plasmids encoding the wildtype or variant FcRn fused with EGFP along with the plasmid encoding b2m were transfected into HeLa cells using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Plasmids encoding wild-type or variant FcRn fused with EGFP were used for all experiments, including the intracellular localization and antibody recycling activity of FcRn.
Western blot analysis: Wild-type and variant FcRn-EGFP transfected into HeLa cells in 35-mmdiameter dishes were lysed with 500 mL of RIPA buffer [50 mM Tris HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40 and 0.25% sodium deoxycholate] supplemented with protease inhibitors (Nacalai Tesque, Kyoto, Japan). After incubation on ice for 30 min, the lysates were centrifuged at 15,000 rpm at 49 C for 20 min. An aliquot (3 mL) of the supernatant was diluted in SDS-sample buffer and applied to 10% SDS-polyacrylamide gel. After electrophoresis, separated proteins were transferred onto polyvinylidene fluoride membrane. Immunochemical detection of FcRn-EGFP proteins was performed using rabbit anti-human FcRn antibody raised against a peptide antigen (residues 135-148, LNGEEFMNFDLKQG). Visualization of the proteins was achieved with horseradish peroxidase-conjugated anti-rabbit IgG antibody (Cell Signaling Technology, Danvers, MA, USA) and the ECL Plus Western blotting detection reagent (GE Healthcare BioSciences AB, Uppsala, Sweden). Protein band densities measured by LAS-3000 (Fuji Film, Kanagawa, Japan) were quantified with Multi Gauge software (Fuji Film).
The relative expression levels are shown as means±SD of three separate transfection experiments. To verify that the samples were evenly loaded, the blot was reprobed with anti-glyceraldehyde-3-phosphate dehydrogenase (G3PDH) antibody (R&D Systems, Minneapolis, MN, USA).
Fluorescent labeling of antibodies: As a model antibody, we used infliximab, a clinically used chimeric anti-human TNFa antibody which has the Fc domain of human IgG1. The binding of infliximab to human FcRn was shown by surface plasmon resonance analysis in our previous study. 3) Infliximab, kindly provided by Tanabe Pharmaceutical Co. Ltd. (Osaka Japan), was labeled with CypHer5 (GE Healthcare Bio-Sciences, Uppsala, Sweden) by incubating with CypHer5E mono NHS ester in PBS containing 0.5 M Na2CO3 (pH 8.3) for 1 hr at room temperature. After the reaction, unbound dye was removed by dialysis in PBS. The protein concentration and degree of labeling were determined by spectrophotometry. IgY (Jackson Immuno Research Laboratories, West Grove, PA, USA) was also labeled with CypHer5 and used in control experiments.
Imaging with fluorescence microscopy: HeLa cells transfected with wild-type or variant FcRn-EGFP cDNA and the b2m cDNA were cultured on 35-mm poly-L-lysine-coated glass-bottom dishes (0.08-0.12 mm thickness) (Matsunami, Osaka, Japan) for 2-4 days. The intracellular localization analyses of wild-type and variant FcRn-EGFP were carried out by confocal laser scanning fluorescence microscopy using a Carl Zeiss LSM510 system (Carl Zeiss, Jena, Germany). For co-localization experiments, wild-type or variant FcRn-EGFP-transfected HeLa cells were incubated with CypHer5-labeled infliximab diluted in cell culture medium containing 200 mM sodium phosphate buffer (pH 6.0) for 2-3 hr at 379 C. Note that throughout this study, the cell culture media used for incubation with the labeled antibody was acidified (pH 6.0) to obtain enhanced incorporation of antibodies into the cells, as reported previously.
6,7)
The fluorescent signal was observed in neutral pH medium after washing the cells twice. The 488-and 633-nm laser lines were used to image FcRn-EGFP and CypHer5 labeled-infliximab, respectively.
Biotin labeling of antibodies: Infliximab and IgY were labeled with biotin using EZ-link sulfo-NHS-biotin (Pierce, Rockford, IL, USA). Antibodies and sulfo-NHSbiotin were mixed at the molar ratio of 1:20 and incubated for 60 min at room temperature. Biotinylated antibodies were purified using Zeba desalt spin column (Pierce). Protein concentration was determined by BCA protein assay (Pierce) using bovine serum albumin as a standard.
Recycling assay: HeLa cells were transfected with the wild-type or variant FcRn-EGFP construct along with the b2m construct. The day after transfection, cells were seeded on 96-well plates at 4×10 4 cells/well. After further culturing for one day, recycling assays were performed. Hanks' balanced salt solutions (HBSS) (pH 6.0 and 7.4) were prepared supplemented with 10 mM MES (pH 6.0) and 10 mM Hepes (pH 7.4). The cells were washed with HBSS (pH 7.4) and pre-incubated with HBSS (pH 7.4) for 30 min at 379 C. After washing with HBSS, 10 mg/ml of biotinylated infliximab diluted in HBSS (pH 6.0) containing 0.5% fish gelatin was added to each well. The cells were incubated at 379 C for 1 hr to allow the antibody to be incorporated into the cells. Cells were then washed five times with HBSS (pH 7.4). Then, HBSS (pH 7.4) supplemented with 2% ultra-low IgG FCS (Invitrogen) was added to each well and incubated at 379 C for the indicated periods of time. The supernatant was collected and subjected to ELISA for quantitating the recycled antibody. In order to determine the amount of biotinylated infliximab incorporated into the cells during the 1-hr incubation at 379 C, cells were lysed using RIPA buffer supplemented with protease inhibitors (Nacalai Tesque, Kyoto, Japan) after washing five times with HBSS, and the lysate was subjected to ELISA. Biotinylated IgY was also used as a negative control in some experiments.
Enzyme linked immunosorbent assay (ELISA) for biotinylated antibody: NeutrAvidin (Pierce, Rockford, IL) was bound on Maxisorp 96-well black plates (Thermo Fisher Scientific, Roskilde, Denmark) using IMMUNO-TEK ELISA construction system (ZeptoMetrix, Buffalo, NY, USA). Supernatants or lysates obtained from the recycling assay were applied on the wells and incubated for 16 hr at 49 C. The plates were washed three times with Tris-buffered saline (pH 7.6) containing 0.1% Tween-20 (TBST). Peroxidase-conjugated goat antihuman IgG (Pierce) diluted with TBST was added to the plate and incubated for 1 hr at room temperature. After washing three times with TBST, chemiluminescent reagent (SuperSignal ELISA Femto, Pierce) was added and incubated for 1 min at room temperature. The chemiluminescent signal was detected using an ARVO 1420 multilabel counter (Perkin Elmer, Waltham MA, USA). When the amount of biotinylated IgY was measured, peroxidase-conjugated rabbit anti-chicken IgY (Promega, Madison, WI, USA) was used. For generation of a standard curve, 0.1 to 10 ng/ml of biotinylated corresponding protein was used.
Results
FCGRT variations found in a Japanese population: Thirty-three genetic variations were found, including 17 novel ones, in 126 Japanese subjects ( Table  2) . Of these variations, 14 were located in the 5?-flanking region, 4 (2 synonymous and 2 non-synonymous) in the coding exons, 13 in the introns, 1 in the 3?-untranslated region (UTR), and 1 in the 3?-flanking region. All detected variations were in Hardy-Weinberg equilibrium 
Fig. 2. Western blotting of wild-type and variant FcRns
Cell lysates obtained from the HeLa cells transfected with wild-type or either of the two variant FcRn-EGFP plasmids were subjected to electrophoresis, followed by transfer to the membrane. Detection of FcRn-EGFP was performed as described in Materials and Methods. One representative data of three independent transfections is shown. The FcRn band (64 KDa) consists of 37 KDa of FcRn and 27 KDa of EGFP. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) levels were used for normalization of the lysate proteins applied to electrophoretic gels.
(pAE0.05). Two novel non-synonymous variations, 629GÀA (R210Q) and 889TÀA (S297T), were found as heterozygotes. The allele frequencies were 0.004 for R210Q and 0.020 for S297T. The functional significance of these non-synonymous variations was explored in vitro in the following sections. The other coding variations were previously reported synonymous variations. A variable number of tandem repeats (VNTR) was detected in the 5?-flanking region as was found in Caucasian subjects, 8) and the frequencies of VNTR3 (with 3 repeats) and VNTR2 were 0.968 and 0.032, respectively. A short tandem repeat of GGAA was also detected in the 5?-flanking region with a repeat number of 8 (frequency: 0.024), 9 (0.103), 10 (0.754), 11 (0.099) and 12 (0.020). With the 12 detected variations with AE0.03 frequencies, linkage disequilibrium (LD) was analyzed using`D?`and r 2 values (Fig. 1) . Because of relatively weak linkage between the variations in r 2 values, haplotype analysis was not performed.
Intracellular localization of FcRn variants: Two novel non-synonymous variations, R210Q and S297T, were functionally tested using a mammalian expression system. First, relative expression levels of wild-type and variant FcRn proteins were evaluated by Western blotting. As shown in Figure 2 , similar levels of the proteins were detected in the three FcRn constructs, and we did not find any statistically significant differences (pÀ0.05) between the wild-type and the two variants assessed by Dunnett's multiple comparison test when normalized by the expression levels of glyceraldehyde-3-phosphate dehydrogenase as a control. When the wild-type levels were set as 100%, R210Q and S297T levels were 95.08± 12.38% and 93.94±13.24%, respectively.
In order to examine the differences of intracellular localization between wild-type FcRn and its variants, each EGFP fusion construct together with a human b2m construct was transfected into HeLa cells, and fluorescent images were observed by confocal microscopy. There have been several studies reporting the intracellular localization or trafficking of FcRn using fluorescent protein-tagged FcRn. [9] [10] [11] [12] N-and C-terminally tagged FcRn showed similar localization. 13) Since FcRn is a type I membrane protein, N-terminal amino acid residues including R210 and S297 were located in the extracellular or intraluminal region. Therefore, we chose a C-terminal EGFP tag located in the cytoplasmic region of FcRn in order to minimize the effect of the fluorescent tag on the structural environment around the mutation sites.
As shown in Figure 3a , the fluorescent signal of wildtype FcRn-EGFP was located primarily in intracellular vesicular components, especially in the perinuclear region. Similar localization was observed for R210Q and S297T variants (Figs. 3c and 3e) , suggesting that these amino acid mutations do not affect the intracellular localization of FcRn.
Intracellular co-localization of FcRn variants and incorporated antibody: We then examined the colocalization of the incorporated CypHer5-labeled infliximab and FcRn-EGFP. The binding of CypHer5-labeled infliximab to FcRn was confirmed beforehand (data not shown).
As shown in Figure 4 , co-localization of FcRn-EGFP and CypHer5-labeled infliximab in intracellular vesicular compartments was observed in HeLa cells expressing wild-type or variant FcRn. Since the fluorescence intensity of CypHer5 increases in acidic pH, 14) the observed fluorescent signal can indicate that CypHer5-labeled infliximab is localized in intracellular acidic compartments such as endosomes. Since the fluorescent images were obtained by confocal microscopy from cells which were washed with neutral pH media, the fluorescence is thought to be derived from incorporated antibodies and not from cell surface-bound antibodies. Therefore, these results showed that both types of FcRn variant, as well as wild-type FcRn, were in acidic endosomes in which incorporated antibodies localized.
Antibody recycling activity of FcRn variants: In order to elucidate the antibody recycling activity of wildtype and variant FcRn, we established the ELISA for biotinylated antibody (infliximab in this study), and measured the amount of recycled antibody from wild-type or variant FcRn-transfected cells. The binding of biotinylated infliximab to FcRn was confirmed by surface plasmon resonance (SPR) analysis (data not shown).
As shown in Figure 5b , recycled biotinylated infliximab was detected when the biotinylated infliximab had been loaded to the HeLa cells transfected with wild-type FcRn. The recycling was not detected in mock-transfected cells (Fig. 5a) , showing that recycling was dependent on expression of FcRn. When the cells were incubated at 49 C for incorporation or recycling, the antibody was not detected in the supernatant. Therefore, recycling was mediated by intracellular trafficking of antibody and not by nonspecific mechanisms. As shown in Figures 5c and  5d , similar levels of antibody recycling were also observed in HeLa cells transfected with either variant FcRn, suggesting similar IgG binding and intracellular trafficking properties of variant FcRns to those of wild-type FcRn. Figure 6 shows the time course of antibody recycling from cells transfected with wild-type or variant FcRn. The amount of incorporated antibody was measured using the cell lysate at 0 min, and it is noteworthy that no statistical differences assessed by Dunnett's multiple comparison test were observed in the amount of incorporated antibodies between wild-type and either variant FcRn at time 0 (data not shown). The amount of recycled antibody at each time point was expressed as a percentage of the initially incorporated antibody. There was no significant difference between wild-type and the variant FcRns in the amount of recycled antibody, suggesting that these amino acid substitutions do not affect the antibody recycling activity of FcRn.
Discussion
In general, antibody therapeutics have longer half-lives than those of chemical drugs, and the T1/2 of IgGs, except for IgG3, in humans is around 21 days. IgG1, IgG2 and IgG4, which are currently used isoforms for antibody therapeutics, have high affinities for FcRn. 15) Escaping from intracellular degradation by binding to FcRn has shown to contribute to this long half-life of the IgGs. 
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FCGRT polymorphisms and functional significance Large interindividual variations in pharmacokinetic parameters have been reported for at least several antibody therapeutics. For example, trough concentrations in repetitive dosing of antibodies were reported to show 5.6-fold interindividual differences in 22 palivizumabtreated patients, 16) 18.2-fold differences in 16 cetuximabtreated patients, 17) and over 70-fold differences in 86 infliximab-treated patients. 18) In addition, large percent coefficients of variation were reported for T1/2, such as 72.0% for gemtuzumab ozogamicin 19) and 76.4% for basiliximab, 20) after second dose of their treatments. We presumed that changes in FcRn expression levels and function caused by genetic variations of FCGRT may lead to these interindividual differences in pharmacokinetics of antibody therapeutics.
In order to identify genetic polymorphisms of FCGRT, we sequenced genomic DNA from 126 Japanese subjects. A total of 33 genetic variations, including 17 novel ones, were detected. A VNTR was detected in the 5? -flanking region, as was the case in Caucasian subjects reported previously. 8) Although a recent study showed that no significant impact was observed in the rates of maternal-fetal IgG transfer, 21) VNTR3 is known to be associated with 1.66-fold higher transcriptional activity than VNTR2 in vitro. In addition, monocytes with VNTR3/3 showed increased binding of IgG compared to those with 2/3. 8) Thus, this variation may contribute to the interindividual differences in pharmacokinetics of antibody therapeutics. The allele frequency of VNTR2 in Japanese (0.032) was lower than that in Caucasians (0.075). 8) In this study, two novel nonsynonymous variations were found and their functional significance was assessed in vitro using a mammalian expression system. However, the two FcRn variants did not show any changes in intracellular localization or recycling, suggesting that the two nonsynonymous substitutions found in a Japanese population probably do not contribute to the interindividual variations in the pharmacokinetics of antibody therapeutics. Since FcRn function is important for maintenance of IgG levels as well as maternal-fetal IgG transfer, functionally-affecting genetic variations might be few to retain its functional capability.
Amino acid residues of human FcRn that interact with IgG were reported to be E138, E139, D153 and W154, in the a2 domain. 1) (Amino acid numbers shown in this paper include the signal peptide.). The electrostatic binding of these anionic amino acid residues in FcRn with H310 and H435 in IgG, which has an isoelectric point of pH 7.6, defines the strict pH-dependent binding of IgG to FcRn. 22) The variant amino acid residues identified in this study, R210Q and S297T, are both located in the a3 domain of FcRn. According to the predicted higher order structure, 1) R210 and S297 are located very close to the transmembrane region that is distant from the IgG binding site. Considering the results obtained here, where no difference in antibody recycling activity between wildtype and each variant FcRn was detected in vitro, the amino acid substitutions identified in a Japanese population may not have significant impact on structural and functional properties of FcRn. Although FcRn is known to bind with albumin as well as IgG, the albumin binding site of FcRn has been identified as H189, which also is located in the a2 domain. 23) The polymorphic sites are also far from the albumin binding site. However, the effect of amino acid substitutions R210Q and S297T on the albumin recycling activity via FcRn should be determined in a future study.
In the present study, we used HeLa cells to examine the localization and recycling activity of FcRn variants. Since endogenous expression of FcRn protein in HeLa cells has not been detected, 24) we considered HeLa cells suitable for examining the antibody recycling activity of variant FcRn since the background responses are negligible. In fact, as shown in Figure 5 , antibody recycling was detected only in FcRn-transfected cells. Therefore, we concluded that HeLa cells can be used as a suitable model for evaluating the function of variant FcRn proteins.
Our results suggested that at least no common functional polymorphic site with amino acid change was present in FCGRT in our Japanese population. Since FcRn function is important for maintenance of IgG levels, there may be few functionally-affecting genetic variations. Further analysis is necessary for the functional significance of transcriptional regulatory regions.
